• 首页
  • 主编简介
  • 编委成员
  • 杂志介绍
  • 杂志稿约
  • 期刊订阅
  • 广告刊登
  • 联系我们
  • English
引用本文:
【打印本页】   【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 890次   下载 165次 本文二维码信息
码上扫一扫!
分享到: 微信 更多
字体:加大+|默认|缩小-
阿尔茨海默病临床治疗研究进展
黄强1, 桑绍明1, 潘晓黎1, 钟春玖1,2
1.复旦大学附属中山医院神经内科, 上海 200032;2.复旦大学脑科学研究院, 脑科学协同创新中心, 医学神经生物学国家重点实验室, 上海 200032
摘要:
阿尔茨海默病(Alzheimer disease, AD)是最常见的神经退行性疾病之一,其高患病率将带来沉重的疾病负担。由于AD的发病机制尚不明确,目前有限的AD治疗药物只能延缓病情进展,却无法逆转病程。近年来,国内外进行了多个药物及非药物干预临床研究,对应的结果也相继披露。本文就近期开展的AD临床诊疗方法进行总结。
关键词:  阿尔茨海默病  药物研发  非药物治疗
DOI:10.12025/j.issn.1008-6358.2023.20222310
分类号:
基金项目:国家自然科学基金面上项目(82171408,82171411),上海市市级科技重大专项(S2021-071).
Advance on the clinical research of Alzheimer’s treatment
HUANG Qiang1, SANG Shao-ming1, PAN Xiao-li1, ZHONG Chun-jiu1,2
1.Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, China;2.Institutes of Brain Science, Collaborative Innovation Center for Brain Science, State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200032, China
Abstract:
Alzheimer disease (AD) is one of the most prevalent neurodegenerative diseases, and its high morbidity would lead to heavy disease burden. As the pathogenesis of AD remains unclarified, current therapies could only slow down the disease progression rather than reverse the disease course. For decades, multiple non-drug treatments have been tested in the clinical trials as well as treatments involving novel developed drugs, and the corresponding outcomes have been disclosed. We reviewed the recently finished and on-going clinical trials focusing on AD in this article.
Key words:  Alzheimer disease  drug development  non-drug treatment
沪ICP备16009103号-3
版权所有:上海《中国临床医学》杂志社有限公司
主办:复旦大学附属中山医院  上海市徐汇区枫林路179号18号楼517  邮政编码:200032
电话:021-51217570  电子邮箱:zglcyx@vip.163.com
技术支持:北京勤云科技发展有限公司

沪公网安备 31010402004907号